Ewing sarcoma is a cancer of bone and soft tissue in children and young adults that is driven by the EWS-ETS fusion transcription factor, most commonly EWS-FLI1. We previously reported that Ewing sarcoma harbors two populations of cells, the CD133 high population displaying higher growth rate and the CD133 low population displaying chemotherapy resistance. We now find that the ubiquitin-specific protease 1 (USP1) is a transcriptional target of the EWS-FLI1 fusion oncoprotein, expressed at high and low levels in the CD133 high and the CD133 low populations, respectively, and determines chemo-sensitivity. We also find that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. We show that chemo-sensitization by USP1 is independent of cdc42. A pharmacological inhibitor of USP1 was able to activate cdc42 and inhibit Ewing sarcoma growth. These results uncover critical roles for USP1 in Ewing sarcoma, which regulates growth and chemo-sensitivity via distinct mechanisms.
Keyphrases
- transcription factor
- young adults
- soft tissue
- photodynamic therapy
- locally advanced
- cell cycle
- nk cells
- small molecule
- cancer therapy
- squamous cell carcinoma
- combination therapy
- bone mineral density
- cell proliferation
- drug delivery
- papillary thyroid
- dna binding
- heat shock
- signaling pathway
- endoplasmic reticulum stress
- bone loss